Press release
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
Lausanne VIII Workshop for Leaders and Innovators in Alzheimer’s will be held, November 15, 2021 - November 18, 2021 NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE)
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Lausanne VIII Workshop for Leaders and Innovators in Alzheimer’s will be held, November 15, 2021 - November 18, 2021\nNEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join the panel, “Exploring the Promise of Novel Therapeutic Approaches,” at the Lausanne VIII Workshop on Wednesday, November 17th at 10:00 a.m. EST to 11:00 a.m. EST. The 2021 Lausanne Workshop for Leaders and Innovators in Alzheimer’s is the eighth in a series of Lausanne-based annual Alzheimer’s convenings with a goal to stop Alzheimer’s by 2025. Over the past seven years, the Workshop has become a highly-curated platform for global Alzheimer’s stakeholders to identify challenges, set solution paths, measure progress and hold each other accountable to act. The Lausanne Workshop is organized under the auspices of the Organisation for Economic Co-Operation and Development (OECD) and supported by The Global CEO Initiative on Alzheimer’s Disease (CEOi), Alzheimer’s Disease International (ADI) and World Economic Forum (WEF). It launched in 2014 as a response to the international call to action to stop dementia by 2025. Click here to register or to learn more about the event. About Alzheimer’s Disease Alzheimer’s disease is a progressive degenerative brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. An estimated 5.7 million Americans currently have Alzheimer's dementia. Alzheimer’s is the most common cause of dementia among older adults and is estimated to rank as the third leading cause of death for older people in the United States, just behind heart disease and cancer. In 2020, Alzheimer's and other dementias cost the nation $305 billion. By 2050, these costs could rise as high as $1.1 trillion.1 There are currently over 50 million people living with dementia around the world, with numbers expected to increase to nearly 152 million by 2050.2 Al...